Skip to main content

LabCorp Becomes Customer of Third Wave s Drug-Metabolism Assay

NEW YORK, Feb. 12 (GenomeWeb News) - LabCorp has become an "early adopter" of Third Wave Technologies' new Invader cytochrome P450 2D6 assay panel, Third Wave said on Tuesday. It is Third Wave's first pharmacogenomics product.

LabCorp will use the assay, which is classified into four drug-metabolism categories, to help drug makers predict drug response in subjects.

The panel comprises SNPs, single and multiple base-pair deletions, and whole gene deletions and duplications in the 2D6 gene family.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.